Vascular occlusion in the nasolabial fold: signs and management
The nasolabial fold (smile lines) is one of the most treated areas with filler and, at the same time, one of the highest in vascular risk. The facial artery climbs the face near the fold and continues as the angular artery beside the nose, giving branches to the nasal ala and upper lip. An occlusion along this course can lead to necrosis of the nasal ala, lip or cheek and, more rarely, to a visual complication.
This guide is a review: anatomy, signs, differentials, how to organize the initial management, and prevention. It includes no doses, dilutions or injection protocols, which follow current guidelines and the decision of the licensed professional, according to the rules of their professional council in Brazil. The procedure is in nasolabial fold filler, and the general concept in the entry vascular occlusion.
Why is the nasolabial fold a risk area?
| Structure | Why it matters |
|---|---|
| Facial artery | Crosses the mandible and climbs toward the corner of the mouth and the nose, near the fold; course and depth vary a lot |
| Angular artery | Continuation of the facial artery beside the nose, up to the inner corner of the eye; communicates with the ophthalmic circulation |
| Lateral nasal artery | Branch to the nasal ala, near the upper part of the fold |
| Superior labial artery | Leaves the facial artery near the corner of the mouth, in the lower part of the fold |
| Ophthalmic artery | Linked to the angular artery; explains the visual risk |
Three features matter in practice:
- Variation in course. In some people the facial artery runs right along the fold, in others more medially or more laterally, in different planes. No course holds for everyone.
- Upper part of the fold, near the nasal ala. This is where the artery tends to be more superficial and where the branches to the nose emerge; it is the stretch most cited in necrosis reports.
- Link to the eye. Through the angular artery, product pushed against the flow can reach the ophthalmic artery.
The fat of the nasolabial compartment and the planes of the area are in layers of the face. The map of risk areas is in vascular danger zones of the face.
What are the signs of occlusion in the nasolabial fold?
| Phase | Most cited signs | Where to look |
|---|---|---|
| During injection | Sudden blanching, disproportionate pain | Fold, nasal ala, upper lip |
| Minutes | Net-like violet color (livedo), coldness, slow capillary refill | Cheek, nasal ala, upper lip on the same side |
| Hours | Darkening, localized swelling, increasing pain | Territory of the facial or angular artery |
| Day one to three | Blisters, pustules, dark scabs | Nasal ala and lip, following the vascular course |
| Following days | Established necrosis, ulceration | Risk of tissue loss in the nasal ala and of scarring |
Look beyond the treated point. In an occlusion of the fold, the first signs often appear on the nasal ala and the upper lip, not on the fold itself. The anesthetic in the product may mask the pain.
How do you tell it from other conditions?
| Condition | How it usually presents | Difference from occlusion |
|---|---|---|
| Expected swelling | Diffuse puffiness in the fold and cheek | Normal color, capillary refill preserved, improves within days |
| Bruise | Well-defined purple patch, changes color | Forms no net, does not blanch, does not follow an arterial territory |
| Herpes | Clustered vesicles, generally on the lip border or in the nostril | Prior burning, no livedo or pallor |
| Infection | Redness, warmth, pain that increase over days | No initial pallor; see infection and biofilm after filler |
| Vascular occlusion | Pallor, then a violet net, increasing pain, nasal ala involved | Arterial territory and progression over hours |
When in doubt, the usual guideline advice is to treat it as a suspected vascular event.
What to do when occlusion is suspected: initial management
At review level, complication protocols usually organize the first response like this:
- Stop the injection immediately.
- Ask about and test vision in each eye separately; any change shifts the priority to immediate referral.
- Examine the fold, nasal ala, upper lip and cheek, comparing with the opposite side: color, capillary refill, temperature.
- Activate the clinic's written protocol, with the complication kit at hand.
- With hyaluronic acid, use hyaluronidase across the whole ischemic area, and not only at the injected point, according to current guidelines and the professional's judgment, reassessing perfusion.
- Adjuvant measures cited in protocols have variable evidence and do not replace the enzyme.
- Systemic medication, when indicated, is a medical decision.
- Record everything: start time, signs, serial photos, actions.
- Do not discharge the patient without signs of reperfusion and without a defined follow-up and contact plan.
After the acute phase, the nasal ala and lip need close follow-up; areas that suffered ischemia can form scabs and change color for weeks, and necrosis calls for wound care with medical evaluation. How to organize the enzyme and team training is covered in hyaluronidase in the clinic. The differences from occlusion in neighboring areas are in vascular occlusion in the nose and vascular occlusion in the lip.
How can the risk be reduced in the nasolabial fold?
- Assess whether the fold is the cause. Often a deep smile line comes from loss of support in the midface; treating the cheekbone can reduce the need for product in the fold itself, which is the highest-risk area. See what softens smile lines.
- Take special care in the upper part of the fold, near the nasal ala.
- Prefer conservative volumes and a reversible product, at the professional's discretion.
- Choose the instrument carefully; the discussion is in cannula or needle. No instrument eliminates the risk.
- Watch the skin throughout the injection, including the nose and lip.
- Have hyaluronidase and the protocol ready before starting.
- Inform the patient about warning signs in the first hours and days.
How to talk about this risk with the patient
The informed consent form should mention vascular occlusion, necrosis and visual complication. There are post-filler instructions for hyaluronic acid to adapt, with legal review and review against your professional council's rules.
And in Harmy?
The full anatomy is on the area page nasolabial fold.
Readiness checklist for nasolabial fold filler
- Cause of the fold assessed: loss of midface support considered.
- Hyaluronidase in the clinic, in date, with a written protocol.
- Complication kit assembled and checked.
- Urgent referral flow, including ophthalmic, defined.
- Previous fillers in the area recorded.
- Standardized photos before the procedure.
- Consent form mentioning occlusion, necrosis and visual complication.
- Patient informed about warning signs and given a contact channel.
Frequently asked questions
Can filler in the smile lines cause necrosis?
It can. The nasolabial fold lies along the course of the facial and angular arteries, and an occlusion there can lead to necrosis of the nasal ala, upper lip or cheek. It is one of the highest vascular risk areas of the face.
What are the signs of a complication in the smile lines?
Sudden pallor, disproportionate pain, then a violet net-like color on the cheek, upper lip or nasal ala, with slow capillary refill. Blisters and dark scabs may appear in the following days.
Can nasolabial fold filler affect vision?
Rarely, but it can. The angular artery communicates with the circulation of the eye, and the product can reach the ophthalmic artery. Any visual change during or after the filler is an emergency.
Why does the nasal ala darken after smile line filler?
The nasal ala is supplied by branches that leave the facial artery near the fold. Darkening, pallor or a violet net there after filling the fold suggests vascular occlusion and calls for immediate evaluation.
Harmy images are illustrative simulations generated by AI from the patient's photo to support the conversation between practitioner and patient. They are not a promise of results. Indication, technique, product and volume are solely the decision of the licensed practitioner. This content is for information only and does not replace a clinical assessment.